key: cord-0938338-vk6ya59c
authors: Tulsian, Nikhil K.; Raghuvamsi, Palur V.; Qian, Xinlei; Yue, Gu; D/O Shunmuganathan, Bhuvaneshwari; Samsudin, Firdaus; Hwa, Wong Yee; Jianqing, Lin; Purushotorman, Kiren; Kozma, Mary M.; Wang, Bei; Lescar, Julien; Wang, Cheng-I; Anand, Ganesh S.; Bond, Peter J.; MacAry, Paul A.
title: Mapping the allosteric effects that define functional activity of SARS-CoV-2 specific antibodies
date: 2021-12-28
journal: bioRxiv
DOI: 10.1101/2021.12.27.474251
sha: 854c6e5b4168dc4af4f9cc0433496568586c8e4f
doc_id: 938338
cord_uid: vk6ya59c

Previous studies on the structural relationship between human antibodies and SARS-CoV-2 have focused on generating static snapshots of antibody complexes with the Spike trimer. However, antibody-antigen interactions are dynamic, with significant binding-induced allosteric effects on conformations of antibody and its target antigen. In this study, we employ hydrogen-deuterium exchange mass spectrometry, in vitro assays, and molecular dynamics simulations to investigate the allosteric perturbations linked to binding events between a group of human antibodies with differential functional activities, and the Spike trimer from SARS-CoV-2. Our investigations have revealed key dynamic features that define weakly or moderately neutralizing antibodies versus those with strong neutralizing activity. These results provide mechanistic insights into the functional modes of human antibodies against COVID-19, and provide a rationale for effective antiviral strategies. Teaser Different neutralizing antibodies induce site-specific allosteric effects across SARS-CoV-2 Spike protein

A detailed understanding of the biologic determinants that underlie antibody-mediated 54 neutralization of SARS-CoV-2 is critical for informing our development and evaluation of 55 prophylaxes (vaccines) and antibody-mediated therapies for COVID-19 (1, 2). The principal target 56 for development of effective antibody-based antiviral approaches is the viral Spike glycoprotein. 57 Spike proteins are embedded into the viral envelope that bind to host receptors and mediate entry 58 into the host cells. Spike proteins form trimers, with each monomer comprising an N-terminal S1 59 and a C-terminal S2 subunit separated by S1/S2 cleavage site (3-5). The S1 subunit of the Spike 60 protein is comprised of an N-terminal domain (NTD), a receptor-binding domain (RBD) and a C-61 terminal region connecting it to the S2 subunit. The S2 subunit has a multidomain architecture 62 divided into fusion peptide (FP), heptad repeats (HR1 and HR2), central helix (CH), 63 transmembrane region and a C-terminal domain. The three RBDs exist in an equilibrium of "up" 64 or "down" positions (4, 6). In the up-position, the residues that contact with human angiotensin (29). Antibodies targeting RBD have two major epitopes -(i) ACE2-receptor binding site or the 80 receptor-binding motif ('RBM') that is readily accessible (8), and (ii) a cryptic epitope that is 81 available only when the RBD is in an 'up '-position (30) . In this study, we have characterized a 82 group of novel human antibodies principally derived from convalescent blood samples and principally discovered from convalescent patients of COVID-19 with the exception of CR3022 98 that was derived from a SARS-CoV-1 patient and 5A6 which was derived from a human phage-99 FAB library. The binding activity of each antibody to SARS-CoV-2 Spike trimer and isolated RBD 100 ('RBDiso') was determined using Quartz Crystal Microbalance (QCM) and enzyme-linked 101 immunosorbent assay (ELISA). As observed by the half-maximal effective concentration (EC50) 102 values, seven of the nine antibodies bound strongly to both Spike trimer and RBDiso (Fig. 1A) . 103 Antibody LSI-CoVA-017 binds strongly to Spike but not RBDiso, suggestive of an epitope outside 104 RBD. Antibody 4A8 binds weakly to Spike and showed negligible binding to RBDiso, consistent 105 with previous studies that show 4A8 binds NTD (36). Next, we determined the binding kinetics of 106 these HuMAbs against Spike trimer and observed high affinity binding with slow off-rates (fig. 107 S1, table S1). The affinity constants (KD) calculated using a 1:1 fit for all HuMAbs were in sub-108 nM range, with LSI-CoVA-017 being the lowest (0.088 nM). The association-dissociation kinetics 109 clearly indicate stable binding of the HuMAbs with the Spike trimer. 110 We next investigated their neutralization efficacies using a pseudovirus neutralization test 111 (PVNT). A neutralization capacity of >50% was considered significant. Correspondingly, we 112 observed differential levels of neutralization, wherein LSI-CoVA-014, LSI-CoVA-015, CoVA-016, and CR3022 showed less than 50% efficacy. On the other hand, 4A8, LSI-CoVA-017, 114 and CoVA2-04 showed significant neutralization capacities, while the highest neutralization was 115 observed for CoVA2-39 and 5A6. On this basis, the antibodies were classified as (i) non-, (ii) 116 weakly-, and (iii) strongly-neutralizing HuMAbs (Fig. 1B) .

Non-neutralizing LSI-CoVA-014, LSI-CoVA-015 and LSI-CoVA-016 bind to cryptic epitope 119 sites on RBD and induce perturbations in Spike trimer structure. 120 The epitopes of the HuMAbs were mapped by comparative HDXMS analysis of complexes 121 with Spike and RBDiso. We observed extensive protection in deuterium exchange across peptides 122 spanning RBD of Spike ('RBDs') and RBDiso, in the presence of LSI-CoVA-014, LSI-CoVA-015, 123 LSI-CoVA-016, CR3022, 5A6, CoVA2-04 and CoVA2-39 antibodies. This indicates binding to 124 either RBM or at a site distal to RBM (Fig. 2, fig. S2 ). Overlapping peptides covering residues 125 361-395 showed large-scale protection against deuterium exchange in both Spike (Fig. 2, fig. S2 126 A, B) and RBDiso complexes with LSI-CoVA-014, LSI-CoVA-015, and LSI-CoVA-016 HuMAbs 127 ( fig. S2 C, D) . This region is distal to the RBM site, indicating that these three antibodies bind 128 RBD, without directly interfering with ACE2 receptor binding to Spike protein. In the Spike 129 trimer, the region spanning residues 361-395 becomes accessible only when the RBD adopts an 130 up-position. These differences in deuterium exchange and the identified epitope sites are similar 131 to those observed for CR3022 antibody ( fig. S2D) , previously characterized as a "cryptic" site 132 binder (30). Interestingly, the HDXMS analysis of these three HuMAbs with Spike and RBDiso 133 showed greater deuterium exchange across peptides spanning the RBM (Fig. 2, fig. S2 ). This behavior. Notably, peptides spanning residues 516-533 showed increased deuterium exchange in 143 the presence of antibodies (Fig. 3A, B, fig. S3 ), confirming that antibody-binding stabilizes RBD 144 in an up-conformation. In this position, many inter-monomer and intra-monomer contacts made 145 by RBD with NTD are broken. In the presence of LSI-CoVA-014, LSI-CoVA-015 or LSI-CoVA-146 016, an overall increase in deuterium exchange was observed for peptides spanning NTD of Spike 147 trimer (Fig. 3, fig. S3 ), indicative of greater solvent accessibility or hydrogen-bond disruption as 148 a result of localized destabilization. Increased deuterium exchange was observed at peptides 149 spanning residues 166-182, which interacts with RBD of a neighboring monomer, and residues 150 289-305 that connects NTD to the central core of the Spike trimer and is indicative of domain 151 movement and disruption of RBD-NTD interactions (Fig. 3 inset, fig. S3B ). In addition to these 152 changes at the S1 subunit, most regions of the S2 subunit also showed increased deuterium 153 exchange in the presence of these three mAbs (Fig. 3A, 3B, fig. S4 ), except the S1/S2 cleavage 154 site that showed decreased deuterium exchange. Prominently, we observed increased deuterium 155 exchange across FP, heptad repeats (HR1 and HR2) and residues 902-916 (Fig. 3 inset, fig. S4 ), 156 which are all essential for inter-monomer interactions within the Spike trimer. Taken together, the 157 conformational changes observed at the NTD and the S2 subunit suggest antibody-mediated 158 allosteric changes across the Spike trimer, which result in its global destabilization that may lead 159 to partial dissociation of adjacent monomers. including CoVA2-04, 5A6, and CoVA2-39, showing direct competition with ACE2 binding (37). 174 However, given that these HuMAbs display various virus-entry neutralization potencies whilst 175 binding to overlapping epitopes, a mechanistic explanation for their contrasting behavior remains 176 elusive, particularly for CovA2-04, a weak neutralizer, as opposed to 5A6 and CoVA2-39 that are 177 strong neutralizers. We therefore monitored the binding of CoVA2-04, 5A6, and CoVA2-39 to the 178 Spike trimer and observed a distinct impact on its conformational dynamics (Fig. 2, 3) . A large-179 magnitude decrease in deuterium exchange was observed for most regions of RBD, particularly 180 the peptide clusters spanning RBM (residues 485-502) of Spike and RBDiso complexes with 5A6,

CoVA2-04 and CoVA2-39 (Fig. 2, fig. S2. fig. S6 ). Interestingly, HDXMS analysis of CoVA2-182 04 and CoVA2-39 complexes with RBDiso showed lower deuterium exchange predominantly for 183 peptides covering RBM, and only minor changes across other regions of RBDiso ( fig. S2E-G) . 184 These results indicate that binding of HuMAbs at RBM induces localized changes which lead to a 185 significant reduction in the structural dynamics of RBD, including the peptides spanning the base 186 and linker regions that connect RBD to the Spike trimer. Notably, the Spike variants of concern 187 contain mutations at different sites including E484K-, N501Y-or K417N/E484K/N501 that are 188 localized at RBM, and are reported to reduce the neutralization efficacy of antibodies (1, 38).

HDXMS analysis of Spike complexes with CoVA2-04, 5A6, and CoVA2-39 HuMAbs 190 revealed that they had similar effects on Spike dynamics, wherein an overall reduction in 191 deuterium exchange kinetics was observed. Peptides covering residues 31-42, 92-110, 177-191, 192 265-276 of NTD showed increased deuterium exchange (Fig. 3C, fig. S6 ). Some of these peptides showed large-scale decreased deuterium exchange (Fig. 3C, fig. S6 ). These sites are essential for 201 the Spike trimer to transition from its pre-fusion state to post-fusion state. Taken together, the 202 HDXMS results provide detailed insights into the mechanism of action of these potent neutralizing 203 antibodies CoVA2-04, 5A6, and CoVA2-39, wherein they compete with ACE2 binding, and 204 induce stabilization throughout the Spike trimer to restrict it mobility. 207 We next investigated the effects of moderate neutralizing HuMAb LSI-CoVA-017 on 208 Spike trimer. In an LSI-CoVA-017-bound state, global protection against deuterium exchange was 209 observed across the Spike trimer (Fig. 3D) , with only a few peptides of the NTD showing 210 deprotection (Fig. 3D, fig. S7A ). Upon closer examination, peptides spanning residues 92-110, Fig. 4B and fig. S13 ). For the amino acid residues interacting with the glycan at N331 and 300 N343, contact frequency maps showed the highest number of contacts and magnitude of contact 301 frequencies made by LSI-CoVA-014 Fab, as compared to those by LSI-CoVA-015 and LSI- CoVA-016 (Fig. 4B, fig. S13 ). Similarly, our MD trajectories of NTD:LSI-CoV-017 have shown 303 prominent interactions between N74, N122 and N149 glycans and Fab molecule. The contact 304 frequency measured among NTD:LSI-CoV-017 Fab show stable interactions with an even larger 305 interaction surface compared to any of the RBD:Fab complexes ( Fig. 4B and fig. S13 ), suggesting 306 a potential role of glycans in forming the antibody epitope.

Based upon our HDXMS-guided docked and simulated models, we next studied the 308 binding of four novel HuMAbs with a deglycosylated Spike trimer. Binding of LSI-CoVA-017 309 was completely abolished upon Spike deglycosylation (Fig. 4C) , in contrast to the minor changes 310 observed in binding of LSI-CoVA-014, LSI-CoVA-015 and LSI-CoVA-016 (Fig. 4C) (fig. S14) . To validate the significance of deglycosylation to RBD-binding HuMAbs, we 315 tested 5A6 as control, which showed partial reduction (fig. S14) . Collectively, these results clearly 316 demonstrate that the LSI-CoVA-017 epitope includes glycan moieties on the Spike protein surface.

For other antibodies (LSI-CoVA-014/LSI-CoVA-015/LSI-CoVA-016/5A6) the primary site of 318 binding were non-glycosylated epitopes, as identified by HDXMS with secondary interactions 319 contributed by glycans (Fig. 4) . These results provide a view contrary to the prevailing notion that 320 glycans only act as a shield for Spike protein to hide epitope sites from host immune recognition.

Our results suggest that non-specific interactions of glycans with the antibodies play a substantial 322 role in stabilizing Fab arm binding at the epitope site. (Fig. 4F, fig. S15 ). This clearly suggests a significant overlap in binding orientation to 332 the epitopes by LSI-CoVA-015 and LSI-CoVA-016, and is in-line with our HDXMS-constrained 333 docking and MD simulations (Fig. 4E, fig. S11, S16) . On the other hand, LSI-CoVA-014 did not 334 prevent binding of LSI-CoVA-015 or LSI-CoVA-016. Docking and MD simulations showed that 335 LSI-CoVA-014 bound to Spike in a different orientation than LSI-CoVA-015 or LSI-CoVA-016, 336 and thus can pair with either LSI-CoVA-015 or LSI-CoVA-016 (Fig. 4, fig. S16, S17) . 337 Competition between RBD-and NTD-recognizing antibodies showed that the binding sites for 338 these two antibody classes do not overlap with each other, as observed for LSI-CoVA-014 and 339 LSI-CoVA-017 with LSI-CoVA-015/LSI-CoVA-016 antibodies (Fig. 4F) . 340 To infer stoichiometry and plausible mechanisms of neutralization, we then modelled the 341 binding of full-length IgGs to Spike using a representative structure of Fab:RBD/NTD from the protein trimer (Fig. 4G) . These results are consistent with our 349 competitive ELISA and neutralization assays (Fig. 4F, fig. S17 ). Additionally, the second Fab arm Overall, our study has identified four novel antibodies isolated from convalescent patients 356 with suboptimal levels of neutralisation efficacy compared to RBM binding antibodies.

Considering the mutually exclusive epitope sites complemented by high affinity binding to Spike 358 protein, it would be of interest to explore the use of antibody cocktails against Spike to induce 359 destabilisation into individual monomers or stabilization to reduce the hinge dynamics in order to 360 effectively neutralise the SARS-CoV-2 or its emerging variants. Synergistic effects of selected 361 HuMAbs used in this study were thus evaluated using the PVNT assay. The selected HuMAbs 362 were used in a pairwise cocktail to study the potential synergistic enhancement in neutralization 363 efficacy. When testing a total concentration of 10 μg/mL and in a 1:9 ratio, the paired MAb cocktail CoV-2 antibodies, we characterized an NTD-binding HuMAb LSI-CoVA-017 and compared it to 385 a well-characterized HuMAb 4A8. Although these do not block virus attachment to ACE2, they 386 still showed moderate neutralization. The principal mechanism is likely the binding of two Fab 387 arms of LSI-CoVA-017 and 4A8 to neighboring Spike proteins leading to antibody-mediated 388 oligomerization or 'aggregation' (Fig. 4, fig. S9 ). Further, stabilization of Spike trimer and 405 SARS-CoV-2-RBD was expressed and purified as described previously(9). Plasmid Sars-Cov-2 441 Spike HexaPro (addgene) was used to transfect HEK 293 cells with polyethylenimine (PEI).

Culture supernatant was harvested on day 7 post transfection. Spike hexapro was purified 443 following the same protocol as described for spike construct expressed by Sf9 cells.

The purity and integrity of the Spike, RBD and the antibodies were determined by denaturing 445 polyacrylamide electrophoresis. 448 Spike was coated at 100 ng/well and RBD at 200 ng/well onto 96-well flat-bottom maxi- 478 Pseudotyped viral particles expressing SARS-CoV-2 Spike proteins were produced using 479 a third-generation lentivirus system. A reverse transfection methodology was used for this assay. (Table S5) . (Table S5-S7) . 

Corresponding full-length IgGs were modelled using Swiss Modeller server using 1IGT and 587 1MCO structures as templates (sequence identity > 90%). 590 Atomic coordinates of RBD and NTD from full-length Spike protein (PDB: 6XR8 (44) Table S4 .

Most of the analysis of trajectories were performed using GROMACS analysis package. individual (i) S1 and (ii) S2 subunits, and (iii) trimeric Spike protein, as indicated. (i) S1 subunit acts as the 832 primary interface with the neutralizing HuMabs, with the epitope sites highlighted in yellow for (A) LSI-833

CoVA-014 and (B) LSI-CoVA-016 binding to the cryptic site on RBD, while (C) CoVA2-39 binds at RBM, 834

SARS-CoV-2 variants, spike mutations and immune escape

Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 662 and cooperatively minimize the escape of mutants

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Site-specific glycan analysis of 668 the SARS-CoV-2 spike

Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-670

Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains

Engineering human ACE2 to optimize binding to the spike protein of SARS 673 coronavirus 2

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 675 receptor

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked 677 by a Clinically Proven Protease Inhibitor

Stabilized coronavirus spikes are resistant to conformational changes 679 induced by receptor recognition or proteolysis

SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targets

Conformational transition of SARS-CoV-2 spike glycoprotein between its closed 683 and open states

Continuous flexibility analysis of SARS-CoV-2 spike prefusion structures

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced 687 vaccine candidate

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 691 vaccine produces protective adaptive immunity in mice

Remdesivir for the Treatment of Covid-19 -Final Report

The Non-Specific Antiviral Activity of Polysulfates to Fight SARS-CoV-2, its Mutants 695 and Viruses with Cationic Spikes

Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of 697 Concern in a Hamster Infection Model

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against

-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and 700 the UK

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal 702 Common Epitopes and Recurrent Features of Antibodies

Glycans of SARS-CoV-2 Spike Protein in Virus Infection and 704

Structural Basis of SARS-CoV-2 706 and SARS-CoV Antibody Interactions

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 708 antibody cocktail

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-710

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape 712 seen with individual antibodies

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-714 RBD spike epitopes

Cell Adhesion Molecules 716 Turned to Pathogen Recognition Receptors

Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-720 2 and SARS-CoV

Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and 722 Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses

An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects 725 against SARS-CoV-2 infection in animal models

Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of 727 syncytia

Human monoclonal antibody combination against SARS coronavirus: synergy 729 and coverage of escape mutants

Potent neutralizing antibodies from COVID-19 patients define multiple 731 targets of vulnerability

A neutralizing human antibody binds to the N-terminal domain of the Spike protein 733 of SARS-CoV-2

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 735 Receptor Binding Domain

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-737 induced sera

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal 739 domain target a single supersite

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Bergwelt-Baildon, 743 Generation of human CD40-activated B cells

Defining the structural basis for human alloantibody binding to human leukocyte 745 antigen allele HLA-A*11:01

Modeller: generation and refinement of homology-based protein structure models

Distinct conformational states of SARS-CoV-2 spike protein

CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and 751 CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field

Comparative Protein Structure Modeling Using MODELLER

In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by 756 three hinges

The ClusPro web server for protein-protein docking

VMD: visual molecular dynamics

GROMACS: High performance molecular simulations through multi-level 762 parallelism from laptops to supercomputers

CHARMM36 all-atom additive protein force field: validation based 764 on comparison to NMR data

Canonical dynamics: Equilibrium phase-space distributions

Polymorphic transitions in single crystals: A new molecular dynamics 768 method

LINCS: A linear constraint solver for 770 molecular simulations

Acknowledgments: 773 We would like to thank Ms. Eve Zi Xian Ngoh for her contribution in discovery and 774 production of 5A6

Funding: This work used computational resources provided by the petascale computer cluster 776 ASPIRE-1 at the National Supercomputing Centre of Singapore (NSCC), the A*STAR 777 Computational Resource Centre (A*CRC) and the supercomputer Fugaku provided by RIKEN 778 through the HPCI System Research Project

598) grants awarded to PAM by National Medical Research Council

LJ 787 Funding acquisition: PAM, PJB 788 Project administration: MMK, PAM 789 Supervision: NKT, JL, CW, PJB, PAM 790 Writing -original draft: NKT, PVR, XQ, LJ 791 Writing -review & editing

A) Plots showing changes in deuterium exchange for (i) non-neutralizing LSI-CoVA-016, (ii) strong-817 neutralizing CoVA2-39, and (iii) moderate-neutralizing LSI-CoVA-017 antibody complexes with RBD or 818 NTD compared to free antigens, at different labelling times as indicated. Pepsin-proteolyzed fragment 819 peptides are represented by a dot and their residue numbers are indicated (Table S6, Fig. S18). A significant 820 value of ± 0.5 D was considered as threshold and indicated by red-dashed line. Epitope sites are highlighted 821 in yellow. (B) Differences in deuterium exchange values are mapped on to the structure of (i, ii) RBD and 822 (iii) NTD shown in surface representation, as per key

LSI-CoVA-017 binds at the NTD. Peptides spanning key regions are highlighted by arrows

Epitopes on RBD

Inset highlights a close-up view of Spike trimer along the 840 transverse axis. Differences are mapped onto all the three monomers of Spike. RBD-binding antibodies 841 (LSI-CoVA-014 and LSI-COVA-016) induce destabilizing effects at the inter-protomer contacts, while 842 RBM-binding CoVA2-39 and NTD-binding LSI-CoVA-017 reduce overall conformational dynamics 843 (shades of blue). Peptides spanning residues 304-317

A) Representative structures from the most populated cluster (cluster 1) from MD simulation trajectories 853 are depicted in two orientations for: RBD (grey) complexes with Fab of (i)

Glycans are shown in ball-and-stick representation. (B) Contact frequencies during simulations 856 between glycan moieties and Fab are mapped onto the structure of each Fab. (C) Plots showing the binding 857 of varying concentrations of (i) LSI-CoVA-014

CoVA-017 antibodies with Spike (red circles) and deglycosylated Spike (blue squares) as determined by 859 ELISA. Average of three individual experiments is represented as mean ± S.E.M. (D) Surface 860 representation (lateral and top views) of Fab LSI-CoVA-014 (brown)

The corresponding full-862 length IgGs were modelled onto the Spike trimer (grey, PDB: 7A98) based on the position of their Fab as 863 determined by cluster analysis. (F) SARS-CoV-2 Spike (0.1 µg) was captured by

LSI-CoVA-016, or LSI-CoVA-017 using ELISA, detected using peroxidase-labelled 865 monoclonal antibodies. A low OD450 value is indicative of impaired binding of the peroxidase-labelled 866 detection antibody, as listed

G) Representation of antibodies binding to different Spike protomers, representative of the 868 competition of LSI-CoVA-015/LSI-CoVA-016 with each other whilst allowing binding of

Competing interests: Authors declare that they have no competing interests. Figs. S1 to S18 801   Tables S1 to S7   802  803